Every 37 seconds, someone in the World dies from cardiovascular disease. For more than 50 years, heart disease has remained the leading cause of death for men, women, and people of most racial and ethnic groups around the world.
Around 30% of all deaths worldwide each year are the result of heart disease. PULS (Protein Unstable Lesion Signature Test) Cardiac Test a 9-protein biomarker-based blood test, developed by California-based Global Discovery Biosciences (GD Biosciences), a biotechnology company that detects and diagnoses early-stage heart disease in asymptomatic patients, today announced its strategic partnership with 7 Dimensions Medical Centre.
During the launch the CEO of the Medical Center Prof. Muthanna Abdul Razzak said “Early detection is the key to lowering heart diseases, and 7DMC continuously strives to bring regional and international expertise to UAE.
With the launch of the new service, 7DMC will help bring prevention and enhanced detection methods for individuals and families in the UAE”.
What is The PULS™ Cardiac Test? The PULS Cardiac Test is a simple, non-invasive blood test that uses 9 protein biomarkers to identify individuals with active, yet undetected subclinical Coronary Heart Disease (the “vulnerable patients”) who are at risk of experiencing an acute coronary event due to endothelial damage leading to unstable lesion rupture, and in whom early intervention can help without replacing any proven screening or diagnostic modalities, not only evaluate the risk of developing coronary heart disease, but can detect a silent damage to the coronary arteries, by a simple blood test collection. The result of the test, with a negative predictive value of 97% will guide us formulating preventive and interventional strategies that improve cardiovascular patient care.
The PULS Cardiac Test empowers physicians to:
Quantify Endothelial Damage: By measuring the body immune response that’s activated by the inflammation or damage to the endothelium/arterial wall.
Predict ACS (Acute Coronary Syndrome): Identifies the asymptomatic “vulnerable” patient who is at risk of ACS (MI, Unstable Angina requiring hospitalization, and Sudden Cardiac Death).
Improve Patient Care: Complements existing diagnostic procedures and enables further evaluation of significantly at-risk patients who might have been missed by current methods. Provides guidance for preventive & intervention strategies that improve patient care.